User:Mr. Ibrahem/Alvimopan
Clinical data | |
---|---|
Trade names | Entereg |
Other names | Alvimopan, Entereg |
AHFS/Drugs.com | Monograph |
MedlinePlus | a608051 |
License data | |
Routes of administration | By mouth |
Drug class | Peripherally acting μ-opioid receptor antagonist[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 6% |
Protein binding | 80% (parent drug), 94% (metabolite) |
Metabolism | Gut microflora-mediated hydrolysis to active metabolite |
Elimination half-life | 10-17 hours |
Excretion | Faeces, urine (35%) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C25H32N2O4 |
Molar mass | 424.541 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Alvimopan, sold under the brand name Entereg, is a medication used to speed recovery from ileus after partial bowel resection with surgical anastomosis.[2] It may be used after either small bowel or large bowel surgery.[1] It is taken by mouth.[1]
Common side effects include heart burn.[2] Other side effects may include a heart attack and low potassium.[2][1] Safety in pregnancy is unclear.[3] It is a peripherally acting μ-opioid receptor antagonist.[1]
Alvimopan was approved for medical use in the United States in 2008.[2] In the United States 15 doses of 12 mg costs about 2,900 USD as of 2022.[4]
References[edit]
- ^ a b c d e "Alvimopan Monograph for Professionals". Drugs.com. Archived from the original on 28 June 2021. Retrieved 14 January 2022.
- ^ a b c d e f g "DailyMed - ALVIMOPAN capsule". dailymed.nlm.nih.gov. Archived from the original on 19 April 2021. Retrieved 14 January 2022.
- ^ "Alvimopan (Entereg) Use During Pregnancy". Drugs.com. Archived from the original on 3 December 2020. Retrieved 14 January 2022.
- ^ "Entereg Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 14 January 2022.